Bizarre Three-Eyed Predator Hunted The Ocean Half a Billion Years Ago
Mosura fentoni possessed three eyes, grasped its prey with spiny claws, ate with a circular, tooth-lined maw, swam with the aid of flippers that lined either side of its body, and had 26 body segments – more than any other radiodont, the extinct group of animals to which it belonged.
Luckily, it would only have been about as long as your finger – most things back then were pretty small. But its segmented tail end has fascinated paleontologists Joe Moysiuk of the Manitoba Museum and Jean-Bernard Caron of the Royal Ontario Museum, who characterized the strange beastie from its fossilized remains in the famous Burgess Shale.
They named Mosura for its resemblance to a moth, even though the relationship is distant and tenuous.
"Mosura has 16 tightly packed segments lined with gills at the rear end of its body," Moysiuk explains. "This is a neat example of evolutionary convergence with modern groups, like horseshoe crabs, woodlice, and insects, which share a batch of segments bearing respiratory organs at the rear of the body."
The oceans of Earth's Cambrian period, between around 539 and 487 million years ago, were a different place than our planet today. That was when life really took off, and the ocean started to thrive.
We don't have many records of that time, but the Burgess Shale is, really, if we're being completely frank, a marvel of fossil preservation. It formed around 508 million years ago, when silty mud flowed across the seafloor, trapping and preserving a large number of organisms as it went.
That mud became a fossil bed known as a Lagerstätte, so exceptional that fine details, soft tissue, and even internal structures were captured in the sediment. It revealed a rich ecosystem filled with mysterious creatures so bizarre that we've often been left baffled and wrong about their anatomy.
In this environment lived the radiodonts, a group of animals that shared a common ancestor with arthropods, but has since gone extinct. This group includes the famous Anomalocaris, a fearsome beast that could have grown up to a meter long. That might not seem very large to us, but back then, when most things were small, it was a giant.
Mosura was not a giant, but it was one-of-a-kind, at least as far as we know. Moysiuk and Caron studied 61 fossilized individuals of the species, and characterized it in detail.
"Very few fossil sites in the world offer this level of insight into soft internal anatomy," Caron says. "We can see traces representing bundles of nerves in the eyes that would have been involved in image processing, just like in living arthropods. The details are astounding."
Of particular interest was the animal's circulatory system. It did not involve veins, as the circulatory systems of vertebrates do, but was instead open, like the circulation of modern arthropods. In crabs, spiders, insects, and other arthropods, the heart simply pumps blood (or hemolymph) into cavities in their bodies, where it swirls around their organs to perform its function.
In Mosura, these cavities are called lacunae. They filled the creature's body, and extended into the swimming flaps that extended from each segment, visible as reflective patches in the fossils.
"The well-preserved lacunae of the circulatory system in Mosura help us to interpret similar, but less clear features that we've seen before in other fossils. Their identity has been controversial," Moysiuk says. "It turns out that preservation of these structures is widespread, confirming the ancient origin of this type of circulatory system."
As for its strange, powerful respiratory system at the rear end of its body, its specialized structure suggests Mosura may have had unique needs. Perhaps its habitat was different from that of other radiodonts, or maybe its hunting methods required enhanced respiratory functions.
This is one of those questions that is impossible to answer without more information. However, Mosura is a beautiful example of the strategies life adopts to thrive according to circumstance.
"Radiodonts were the first group of arthropods to branch out in the evolutionary tree, so they provide key insight into ancestral traits for the entire group," Caron says. "The new species emphasizes that these early arthropods were already surprisingly diverse and were adapting in a comparable way to their distant modern relatives."
The research has been published in Royal Society Open Science.
Earth's Rotation Is Slowing Down, And It Might Explain Why We Have Oxygen
New Jersey Hawk Develops Clever Hunting Strategy Using Traffic Signals
Your Sensitive Teeth May Exist So Ancient Fish Could Avoid Danger
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Gizmodo
16 hours ago
- Gizmodo
People Are Now Seeing ‘Zombie' Squirrels in Their Backyards
As if black-horned rabbits weren't strange enough, people are now spotting zombie-like squirrels covered in odd, sometimes bleeding sores in their backyards and parks. These sickly squirrels aren't zombies, however, but victims of a real viral disease. Residents in both Canada and the U.S. have recently reported sightings of the zombie squirrels, dating back to at least 2023. These animals are likely carrying a germ known as the squirrel fibroma virus (SFV). Though the condition is scary-looking, squirrels usually recover from the infection, and it poses no threat to humans. Colorado Residents Are Spotting Weird-Looking Rabbits With Black Horns and Mouth Tentacles SFV was first discovered in the 1950s and is a poxvirus, meaning it's related to the virus that causes smallpox in humans. That said, it's a part of a genus, leporipoxvirus, whose only known natural hosts are squirrels and rabbits. The infection causes the formation of benign tumors, or fibromas, to form across the squirrel's skin, particularly on its head or limbs. The virus is thought to primarily spread through the bites of mosquitos and fleas, but it may also be transmitted through close direct contact with an infected squirrel. It predominantly affects gray squirrels, though it can infect other species as well. SFV can be a dangerous disease for squirrels. The tumors can potentially metastasize to the animal's internal organs or become so large and numerous on the skin that they cause secondary infections or even hamper the animal's vision and ability to eat. But according to the Michigan Department of Natural Resources, the infection typically doesn't cause any obvious signs of illness outside of the skin fibromas. And in areas where it is common, like Michigan, the virus hasn't had any effect on the overall squirrel population. In most cases, the fibromas regress over time, and the animal recovers completely. If you're a hunter with a hankering for squirrel meat, you can also rest easy. Even SFV-infected squirrels are apparently safe for consumption, according to the Michigan DNR. Still, the average person shouldn't try to touch or handle infected squirrels, or really any wildlife for that matter. On a little side note, SFV is sometimes called the squirrel pox virus. But this is also the nickname for a different pox virus (the squirrelpox virus) that predominantly affects squirrels in the UK. Adding to the confusion, researchers have identified other potential squirrel pox viruses in countries like Canada and Germany. All of which is to say: It feels like there should be a cleaner labeling system for these squirrel-related diseases.
Medscape
17 hours ago
- Medscape
Do Comorbidities Shape MS Outcomes?
This transcript has been edited for clarity. Thanks so much for the opportunity to talk to you today about the effects of comorbidity in people living with multiple sclerosis (MS). My name is Ruth Ann Marrie. I'm a professor of medicine and community health and epidemiology, and the Multiple Sclerosis Clinical Research Chair at Dalhousie University. Today, I'd like to talk to you about what comorbidities often affect people with MS, how often they occur, and the effects of comorbidity on MS-related outcomes. When we talk about comorbidity, we're referring to the total burden of illness other than the specific disease of interest. In our case, MS is the disease of interest, so the comorbidities could include diabetes or hypertension, for example. We exclude from this definition complications that are secondary to MS, like urinary tract infections due to neurogenic bladder. Why? Well, it has importance in terms of thinking about the clinical target. Common Comorbidities in MS: What Can We Learn? Why, more broadly, are we interested in studying comorbidity? Comorbidity may help us to better explain the difference in outcomes between people with MS; we know outcomes are highly heterogeneous. It may help us better prognosticate and make treatment decisions for people with MS. It may also give us insights into the pathogenesis of MS. If we found that diabetes was associated with worse outcomes, we might think about how diabetes affects the brain in terms of its effects on the endothelium, for example, or the role of insulin receptors, and that might then lead to new treatment avenues. What do we know about comorbidity in MS at the present time? We know it's present throughout the disease course, and people with MS actually have a higher burden of some comorbidities even before they present with their first clinical symptoms. We've seen that people with MS have an increased incidence of psychiatric disorders, for instance, five to 10 years before their first clinical presentation. At the time of an MS diagnosis, the most common conditions that we see are depression, hypertension, chronic lung disease (particularly asthma), and anxiety disorders. Depending on the age of the individual with MS at the time of their initial presentation, the prevalence of those conditions may exceed 15%. Overall, we think at least 1 in 4 people with MS have a comorbid condition at diagnosis. If we take a random snapshot of any prevalent MS population, then the most common comorbidities we see are similar to those that we see at diagnosis, with depression and anxiety disorders as well as hypertension being prevalent. Hyperlipidemia and irritable bowel syndrome are also present. An important issue is how the prevalence of those conditions evolves over the course of MS. About 20%-30% of people with MS are going to have depression or an anxiety disorder at any given point in their disease course. In contrast, conditions like hypertension, hyperlipidemia, and diabetes are going to increase in prevalence with age. This means people are typically going to have a much higher burden of comorbidity later in their disease course when it's already becoming more difficult to manage their MS, and they may be taking many symptomatic therapies. You might say, well, they're common and we have to worry about polypharmacy between managing the comorbidities and the symptoms of MS, but what's the actual impact on outcomes? Comorbidities and Disease Progression Well, there's been a large amount of work to show that cardiometabolic and psychiatric comorbidities affect multiple outcomes in MS, ranging from delays in the time from symptom onset to diagnosis, the severity of disability at diagnosis, the rapidity of disability progression and lifespan, and quality of life. I'm going to focus on a couple of those for today — specifically, relapses and disability progression. Multiple studies suggest that comorbidity influences relapse rates and the rate of disability worsening. One of the earliest studies was done at the State University of New York at Buffalo by Bianca Weinstock-Guttman and colleagues. It suggested that if you had dyslipidemia, you had faster disability progression and faster accrual of new hyperintense T2 lesions on MRI. Some subsequent studies — for instance, one done by Dr Kyla A. McKay and colleagues — found that among individuals with psychiatric comorbidity, their disability progressed faster. She [and her colleagues linked data from two Canadian clinical and population-based health administrative databases] and, using these datasets, followed over 2000 people for an average of about 10 years. For people who had a mood or anxiety disorder, they accrued nearly 0.3 more Expanded Disability Status Scale (EDSS) point per year than people without psychiatric comorbidity. You might think, well, that's not very much. When you consider that most people with a psychiatric disorder are going to face that long term, you think about that over a 10-year time horizon, that's the difference of about 3 EDSS points. That's the difference between mild and moderate disability, so it's quite substantial. Similar findings have been reported looking at physical comorbidities as well. There was a fairly recent study done by Dr Amber Salter, who is based at UT Southwestern, and colleagues, using meta-analysis of clinical trial datasets. It included 17 trials involving almost 17,000 people with MS. The advantage of this dataset is that people in clinical trials are followed very closely and rigorously, with frequent assessments. She and her colleagues identified comorbidities at the time of enrollment in the clinical trials, and 61% of participants in the trials had some evidence of disease activity, whether it was relapses, disability worsening, or new lesions on MRI. Individuals who had three or more comorbidities had a 14% increased rate of disease activity. Having two or more cardiometabolic comorbidities was associated with a 21% increased rate of any disease activity. When they looked at individual comorbidities, they found that depression and ischemic heart disease seemed to be the biggest driver of those effects. This is really important to think about when you look specifically at relapses. More comorbidities were associated with more relapses. They also found that more comorbidities were associated with faster disability worsening. This really points to the adverse impact of comorbidity on outcomes in MS. This is an example of a longitudinal design, rigorously assessed, so it reduces concerns about the concept of reverse causality — that is, that people with more severe MS may be more likely to accrue comorbidities because they're less physically active, they're not able to eat as well, and so on. The design doesn't fully mitigate that concern. There's another recent study, by Dr Kaarina Kowalec and colleagues, which tried to address this issue by using polygenic scores as an instrumental variable. Polygenic scores are basically weighted averages of all the variants that would be associated with a particular outcome — in this case, depression. The nice thing about using genes is that they are assigned to us at birth. MS couldn't cause those genes to be assigned. If we can show that the polygenic score for depression is associated with relapses and disability progression in the same way that having depression is, then we can remove that concern about reverse causality. In fact, the study findings suggest that's the case. When we put all of these kinds of findings together, they strongly suggest that there is an important role for comorbidities in influencing outcomes and that we really need to intensify our focus on preventing or mitigating those comorbidities as a means of improving outcomes in people with MS. A key question will be, 'What's the best way to do that?' Is it by simply treating these comorbidities the way we normally would, or do we need to treat them more aggressively? Does the type of intervention for those comorbidities matter in terms of achieving that goal of improving outcomes? I think we really need to begin to think about how to integrate these concepts into routine clinical practice. For that, guidelines and tools will be necessary to reach those goals. Thank you so much for your attention today.
